Filing Details

Accession Number:
0001213900-24-079121
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-09-16 20:48:44
Reporting Period:
2024-09-12
Accepted Time:
2024-09-16 20:48:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1711754 Inmune Bio Inc. INMB Biological Products, (No Disgnostic Substances) (2836) 475205835
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1767280 Joseph Raymond Tesi C/O Inmune Bio Inc.
225 Ne Mizner Blvd., Suite 640
Boca Raton, FL 33432
President And Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-09-12 15,380 $6.38 1,554,106 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Warrants (right to buy) Acquisiton 2024-09-12 15,380 $0.13 15,380 $6.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
15,380 2030-03-16 No 4 P Direct
Footnotes
  1. The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $6.50, for an aggregate purchase price of $13,000,000 pursuant to a securities purchase agreement dated September 12, 2024. The Warrants are exercisable on or after March 16, 2025 and will terminate on March 16, 2030 unless such termination is accelerated pursuant to the terms of the Warrants (the "Termination Date"), provided, however, in the event that the Warrant is held by Insiders and the Termination Date is during a period that such Insiders are subject to a blackout with respect to trading in the Company's common stock, such Insiders will have an additional 60 days from the termination of the blackout to exercise the Warrant. The exercise price the Warrants is $6.40 per share subject to adjustment as provided in the Warrant.